Randomized trial to assess immunogenicity and safety of haemophilus influenzae type B and neisseria meningitidis serogroups C and y-tetanus toxoid conjugate vaccine in infants

Pediatric Infectious Disease Journal

Volumn 29, Issue 1, 2010, Pages 48-52

  Marchant, Colin D ^a   Miller, Jacqueline M ^b,c   Marshall, Gary S ^d   Blatter, Mark ^e   Aris, Emmanuel ^b,c   Friedland, Leonard R ^b,c   Boutriau, Dominique ^b,c  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d University of Louisville School of Medicine   (United States)

^e Primary Physicians Research   (United States)

Author keywords

Haemophilus influenzae type b; Meningitis; Neisseria meningitides serogroups C and Y; Primary vaccination; Vaccine

Indexed keywords

BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B NEISSERIA MENINGITIDIS TETANUS TOXOID CONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE TYPE B TETANUS TOXOID CONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B ANTIBODY; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; TETANUS TOXIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; MULTICENTER STUDY; PERTUSSIS; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; TETANUS; VACCINATION;

EID: 74049124340     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181c3ce88     Document Type: Article

References (32)

1. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance. Available at: http://www.cdc.gov/ncidod/dbmd/abcs/survreports. htm. Accessed September 19, 2008.
2. Lingappa JR, Rosenstein N, Zell ER, et al. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. Vaccine. 2001;9:4566-4575.
3. Centers for Disease Control and Prevention. Notice to readers: revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11-18 years with Meningococcal Conjugate Vaccine. MMWR. 2007;56:794-795
4. Centers for Disease Control and Prevention. Notice to readers: recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of Quadrivalent Meningococcal Conjugate Vaccine (MCV4) in children aged 2-10 years at increased risk for invasive meningococcal disease. MMWR. 2007;56:1265-1266.
5. Marshall GS, Happe LE, Lunacsek OE, et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26: 496-500.
6. Kalies H, Grote V, Verstraeten T, et al. The use of combination vaccines has improved the timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25:507-512.
7. Happe LE, Lunacsek OE, Kruzikas DT, et al. Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population. Pediatr Infect Dis J. 2009;28:98-101.
8. Nolan T, Lambert S, Roberton D, et al. A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. Vaccine. 2007;25:8487-8499.
9. Maslanka SE, Gheesling LL, Libutti DE, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol. 1997;4:156-157.
10. Ostergaard L, Lebacq E, Poolman J, et al. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine. 2009;27:161-168.
11. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129: 1307-1326.
12. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from post-licensure surveillance in England. Clin Diagn Lab Immunol. 2003;10:780-786.
13. Santos G, Deck R, Donnelly J, et al. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol. 2001;8:616-622.
14. Borrow R, Andrews N, Goldblatt D, et al. Serological basis for use of meningococcal serogroup C conjugate vaccines for the United Kingdom: reevaluation of correlates of protection. Infect Immun. 2001;69:1568-1573.
15. Gheesling LL, Carlone GM, Pais LB, et al. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J Clin Microbiol. 1994;32:1475-1482.
16. Peltola H, Mäkelä H, Käyhty H, et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med. 1977;297:686-691.
17. Amato Neto V, Finger H, Gotschlich EC, et al. Serologic response to serogroup C meningococcal vaccine in Brazilian preschool children. Rev Inst Med Trop Sao Paulo. 1974;16:149-153.
18. Concepcion N, Frasch C. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol. 2001;8:266-272.
19. Henckaerts I, Goldblatt D, Ashton L, et al. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with or without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol. 2006;13:356-360.
20. Sato Y, Sato H, Izumiya K Role of antibody to filamentous hemagglutinin and to leukocytosis promoting factor-hemagglutinin in immunity to pertussis. In: Robbins JB, Hill JC, Sardoff JC, eds. Seminars in Infectious Disease: Bacterial Vaccines. New York: Thierne-Stratton, Inc.; 1982:380-385.
21. Granström M, Thorén M, Blennow M, et al. Acellular pertussis vaccine in adults: adverse reactions and immune response. Eur J Clin Microbiol. 1987;6:18-21.
22. Camargo ME, Silveira L, Furuta JA, et al. Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum. J Clin Microbiol. 1984; 20:772-774.
23. Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand. 1983;11:137-144.
24. Frisch-Niggemeyer W, Ambrosch F, Hofmann H. The assessment of immunity against hepatitis B after vaccination. J Biol Stand. 1986;14:255-258.
25. Szmuness W, Stevens CE, Zang EA, et al. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology. 1981;1:377-385. (Pubitemid 12218155)
26. World Health Organization. Standard procedure for determining immunity to poliovirus using the microneutralization test. WHO/EPI/Gen 93.9. Geneva, Switzerland: World Health Organization; 1993.
27. Dagan R, Eskola J, Leclerc C, et al. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun. 1998;66:2093-2098.
28. Dagan R, Poolman JT, Zepp F. Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates. Expert Rev Vaccines. 2008;7:97-115.
29. Rennels M, King J, Ryall R, et al. Dosage escalation, safety and immuno-genicity study of four dosages of a tetravalent meningococcal polysaccha-ride diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J. 2004;23:429-435.
30. Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA. 2008;299:173-184.
31. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunoge-nicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants. Pediatr Infect Dis J. 2001;20:153-159.
32. MacLennan JM, Shackley F, Heath PT, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA. 2000;283: 2795-2801.